Summit Lens

GLP-1 proved the science could work. The harder test began once patients tried to get it.In this episode, we follow GLP-1 from the pharmacy counter into the real world of American healthcare: insurance coverage, compounding pharmacies, PBM formulary decisions, employer benefit design, cash pay pathways, TrumpRx, and public policy.The question is no longer only whether these drugs work. It is how the system decides who gets access when a treatment is effective, expensive, highly demanded, and potentially preventive.And for many patients, the answer depends on which door is actually open.Timestamps00:06  When the Prescription Isn’t Enough07:47  How Compounding Became the Workaround10:58  Why Coverage Still Creates Friction16:17  Public Coverage and International Contrasts21:53  PBMs, Employers, and the Formulary Fight28:56  Cash Pay, TrumpRx, and New Access Lanes35:19  The Pipeline Keeps Moving35:48  Who Pays for Prevention?

How did a gut hormone that disappeared in seconds become one of the biggest drug classes in the world?In this episode, I walk through the story of GLP-1, from early scientific discovery and the Gila monster breakthrough to Novo Nordisk’s drug design strategy, Eli Lilly’s competitive push, and the shift that turned GLP-1 from a diabetes treatment into something much bigger.This is a story about how a hard biological problem became a pharmaceutical platform, and how that platform began to change the way medicine thinks about obesity, metabolism, and chronic disease.Timestamps00:08 Intro: The 90-Second Hormone02:23 The Gut’s Hidden Signal05:01 The Discovery of GLP-110:32 The Gila Monster Breakthrough16:04 Novo Solves the Delivery Problem19:43 How GLP-1 Became a Platform25:46 Beyond Diabetes30:28 Lilly Raises the Benchmark32:43 The Broader Implications of GLP-143:22 The future of GLP-149:14 When the Science Meets the System

What does it actually take to turn a scientific breakthrough into a drug patients can access?In this episode, I look at the manufacturer side of the healthcare system, the part that absorbs scientific failure, funds long-shot bets, and then enters a second battle after the science succeeds. Because FDA approval is not the finish line. It is the point where a therapy enters the real commercial system: one shaped by patent clocks, launch pricing, payer resistance, formulary access, rebates, and budget pressure.This is a story about the economics of failure, the logic of blockbuster drugs, and the central tension at the heart of modern pharma: scientifically essential, politically unpopular, financially powerful, and commercially constrained at the same time.Between the lab bench and the patient sits a market that does not simply reward innovation. It prices it, filters it, delays it, and redistributes its value.Timestamps00:00 Intro: The Drug Exists. Access Still Breaks Down05:44 FDA Approval Is Not the Finish Line09:41 Inside the R&D Risk Machine13:24 Why Most Drug Trials Fail15:32 The Patent Clock Starts Early24:39 Why U.S. Drug Prices Run Higher29:19 The Gross-to-Net Bubble40:16 The Pharma Paradox44:05 The IRA Changes the Game50:59 Invention Is Not Enough

If your doctor writes a prescription, who actually decides whether you get it, where you fill it, and what you pay?In this episode, I unpack the hidden role of pharmacy benefit managers, or PBMs, the intermediaries that sit between drugmakers, insurers, employers, pharmacies, and patients. PBMs do not invent drugs or prescribe them, but they often control formularies, prior authorization, specialty pharmacy channels, and the financial terms that shape access. I trace how PBMs evolved from claims processors into powerful gatekeepers, explain how rebates, spread pricing, specialty pharmacy, and step therapy work, and examine the central debate: are PBMs lowering costs, or making the system more opaque while controlling who gets what medicine? From insulin and biosimilars to specialty drug markups and the latest reform pressure, this is a story about the financial architecture between the prescription pad and the patient.Timestamps00:00 — Cold open03:23 — The pharmacy counter mystery12:28 — Meet the PBM16:35 — The evolution of PBMs22:25 — How the machine works38:01 — Why PBMs grew so powerful49:33 — Critics vs. Defense57:01 — What this means

What happens when an insurance company stops acting like a payer and starts acting like infrastructure?In this episode, I explore how private insurers became some of the most powerful actors in American healthcare. Using UnitedHealth Group as a central case study, I trace the shift from passive bill payer to managed care gatekeeper to vertically integrated healthcare empire. From Medicare Advantage and self-funded employer plans to Optum, PBMs, and the Change Healthcare crisis, this is a story about how private insurers scaled, consolidated, and embedded themselves into the plumbing of the U.S. health system. Timestamps00:10 The role of health insurance in healthcare07:02 The shift to managed care11:00 Understanding UnitedHealth Group’s strategy22:55 The impact of Medicare Advantage33:25 Self-funded plans and pharmacy benefit managers44:28 The vulnerability of consolidation50:45 The corporate takeover of healthcare

Why does getting care in America so often feel like navigating a maze?In this episode, I unpack the hidden architecture behind that confusion. U.S. healthcare is not one coherent system. It is a patchwork of rulebooks built over time through employer-sponsored insurance, Medicare, Medicaid, the ACA Marketplace, ERISA, and decades of political compromise. The result is a system where your job, age, income, disability status, or state can shape not just who pays, but which rules you live under.  This episode explores why public programs increasingly flow through private managed care, why reform so often adds new layers instead of replacing old ones, and why complexity itself has become part of the business model of American healthcare. Timestamps00:00 Why healthcare feels like a maze07:48 How the patchwork was built18:20 Five rulebooks, one system33:10 Why reform adds more layers46:37 The human cost of complexity49:34 Three takeaways

Why does the United States spend more on healthcare than any other country in the world, and still underperform on many basic health outcomes?In this episode, I unpack the machinery behind the high cost of American healthcare. From employer-sponsored insurance and tax policy to hospital consolidation, administrative complexity, and market power, this is a story about how the U.S. built a system that is extraordinarily expensive, highly fragmented, and remarkably hard to fix.This episode is not just about prices. It is about the architecture underneath them, the incentives, institutions, and historical decisions that made the system what it is today.Timestamps00:00 The Start of a Healthcare Journey01:45 Intro: Understanding the Cost of Healthcare04:13 The Economics of Healthcare Spending12:09 The Historical Context of Employer-Based Insurance16:47 The Fragmentation of the Healthcare System]23:27 Administrative Costs and Market Power30:24 The Role of Pharmaceuticals in Healthcare Costs35:36 Return on Investment in Healthcare40:36 Conclusion